BTIG Starts Obalon Therapeutics (OBLN) at Buy

October 31, 2016 7:53 AM EDT
Get Alerts OBLN Hot Sheet
Price: $11.35 +0.18%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade OBLN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BTIG initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $20.

Analyst Sean Lavin said, "The obesity market is huge and growing. Technologies, surgeries, and pharmaceuticals prior to intragastric balloons have either been ineffective, unsafe, too costly, or irreversible. We believe OBLN’s balloon technology addresses many of the issues and will see strong adoption in the fight against obesity. The safety profile, minimal invasiveness, and reversibility all should be favored by physicians and patients. We believe the device will be used for both weight loss leading to significant medical benefits and by patients seeking small cosmetic benefits. Obalon really has shots on goal at two markets and, we think, will succeed at gaining traction in both. We see Obalon as targeting a multibillion dollar market opportunity."

For an analyst ratings summary and ratings history on Obalon Therapeutics click here. For more ratings news on Obalon Therapeutics click here.

Shares of Obalon Therapeutics closed at $13.80 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities


Add Your Comment